⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
APLS News
Apellis Pharmaceuticals, Inc. Common Stock
Inflammasome Therapeutics Completes Enrollment of Multicenter Phase II Dose- Ranging Study for First-in-Class Dual Inflammasome Inhibitor, K8, to Treat Geographic Atrophy
businesswire.com
APLS
Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences
globenewswire.com
APLS
Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years
globenewswire.com
APLS
Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference
globenewswire.com
APLS
Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results
globenewswire.com
APLS
Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results
globenewswire.com
APLS